GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
4
Nexwise Intelligence China
301248
5
Astro-century Education & Technology
300654
US Stock MarketDetailed Quotes
LGVN Longeveron
- 1.700
- -0.020-1.16%
Close Jan 23 16:00 ET
- 1.750
- +0.050+2.94%
Post 20:01 ET
25.22MMarket Cap-0.30P/E (TTM)
1.786High1.660Low253.30KVolume1.700Open1.720Pre Close429.22KTurnover2.17%Turnover RatioLossP/E (Static)14.84MShares7.90652wk High0.98P/B19.85MFloat Cap0.77152wk Low--Dividend TTM11.68MShs Float450.000Historical High--Div YieldTTM7.33%Amplitude0.770Historical Low1.694Avg Price1Lot Size
About Longeveron Company
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.
Company Profile
SymbolLGVN
Company NameLongeveron
Listing DateFeb 12, 2021
Issue Price10.00
Founded2014
CEOMr. Mohamed Wael Ahmed Hashad
MarketNASDAQ
Employees25
Fiscal Year Ends12-31
AddressLife Science & Technology Park,1951 Northwest 7th Avenue,Suite 250
CityMiami
ProvinceFlorida
CountryUnited States of America
Zip Code33136
Phone1-305-909-0840
Websitehttp://www.longeveron.com
Company Executives
- Name
- Position
- Salary
- Mohamed Wael Ahmed Hashad
- Chief Executive Officer and Director
- 1.58M
- Lisa Locklear
- Treasurer, Chief Financial Officer and Principal Accounting Officer
- 380.78K
- Dr. Joshua M. Hare, M.D.
- Chief Science Officer and Chairman of the Board
- 75.31K
- Dr. Nataliya Agafonova
- Chief Medical Officer
- --
- Lisa McClain-Moss
- Vice President, Manufacturing
- --
- Neil E. Hare
- Director
- 40.31K
- Neha Motwani
- Director
- --
- Dr. Roger Hajjar
- Director
- --
- Rock Soffer
- Director
- 43.81K
- Ursula Ungaro
- Independent Director
- 50.81K
- Khoso Baluch
- Independent Director
- 35.97K
- Richard N. Kender, M.B.A.
- Independent Director
- --
- Paul Lehr
- General Counsel and Secretary
- 554.06K
Trending Stocks
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day